Form 4: Aquestive Therapeutics COO Reports Share Transactions

Aquestive Therapeutics' Chief Operating Officer, Cassie Jung, reported the sale of 44 shares of common stock and indirect ownership of 2,000 shares through her spouse.

Summary

• Cassie Jung, the Chief Operating Officer of Aquestive Therapeutics, reported a transaction involving the company's common stock.
• On November 26, 2024, Ms. Jung sold 44 shares of common stock at a price of $4.865 per share.
• Ms. Jung also reported indirect ownership of 2,000 shares held by her spouse and 233,066 shares directly owned.
• The shares held by her spouse are disclaimed by Ms. Jung for beneficial ownership purposes.
• The transaction was reported on a Form 4 filing with the SEC.

Sentiment

Score: 5

Explanation: The document is a neutral report of insider trading activity, with no positive or negative implications for the company's performance.

Industry Context

This is a routine filing related to insider trading and is common for publicly traded companies. It provides transparency into the transactions of company executives.

Comparison to Industry Standards

• Form 4 filings are standard practice for publicly traded companies in the US, as mandated by the SEC.
• The reporting of insider transactions is a common practice across all publicly listed companies, and this filing is consistent with those standards.
• The level of detail provided in this filing is consistent with other Form 4 filings.

Stakeholder Impact

• This filing provides transparency to shareholders regarding the trading activities of company executives.

Key Dates

Keywords

Aquestive Therapeutics, AQST, insider trading, Form 4, SEC filing, stock transaction, beneficial ownership, Cassie Jung, Chief Operating Officer